Compare · HCWB vs NVO
HCWB vs NVO
Side-by-side comparison of HCW Biologics Inc. (HCWB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCWB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 45128.4x HCWB ($4.8M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for HCWB).
- NVO has more recent analyst coverage (25 ratings vs 1 for HCWB).
- Company
- HCW Biologics Inc.
- Novo Nordisk A/S
- Price
- $2.51+13.06%
- $48.65+3.65%
- Market cap
- $4.8M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 9
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HCWB
- HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
- SEC Form S-1 filed by HCW Biologics Inc.
- SEC Form 10-Q filed by HCW Biologics Inc.
- HCW Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
- Amendment: SEC Form 10-Q/A filed by HCW Biologics Inc.
- HCW Biologics Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- SEC Form D filed by HCW Biologics Inc.
- Chief Executive Officer Wong Hing C bought $59,998 worth of shares (23,210 units at $2.58), increasing direct ownership by 23% to 125,845 units (SEC Form 4)
- SVP of Business Development Flowers Lee bought $19,998 worth of shares (7,736 units at $2.58), increasing direct ownership by 810% to 8,691 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S